Wyeth Pharmaceuticals submits extended release antidepressant to FDA

Wyeth Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) with the US Food and Drug Administration (FDA) for desvenlafaxine extended release (DVS-233) for the treatment of major depressive disorder (MDD).

The new treatment is designed for the treatment of major depressive disorder in patients with a broad range of symptoms associated with depression, including both emotional and somatic symptoms.

“We know from clinical studies as well as clinical practice that there remain significant unmet needs in treating depressed patients,” said Gary Stiles, executive vice president, chief medical officer, Wyeth.

“If approved, desvenlafaxine extended release will offer physicians a new clinically proven option for treating depression.”

Depression is the most common serious mental disorder worldwide and affects approximately 121 million people, making it the fourth leading cause of disability and premature death.

© Adfero Ltd